QR kód

Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease

BackgroundCachexia is associated with poor prognosis in chronic liver disease (CLD), yet robust predictors remain poorly defined. This study examined clinical factors and serum biomarkers associated with cachexia in patients with CLD.MethodsWe analyzed 356 of 526 patients with CLD who had complete c...

Celý popis

Uloženo v:
Hlavní autoři: Takatsugu Tanaka, Goki Suda, Masatsugu Ohara, Osamu Maehara, Tomoka Yoda, Qingjie Fu, Zijian Yang, Naohiro Yasuura, Akimitsu Meno, Takashi Sasaki, Risako Kohya, Takashi Kitagataya, Naoki Kawagishi, Masato Nakai, Takuya Sho, Shunsuke Ohnishi, Naoya Sakamoto
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2026-02-01
Edice:Frontiers in Nutrition
Témata:
biomarker
cachexia
chronic liver disease
fibroblast growth factor
liver cirrhosis
On-line přístup:https://www.frontiersin.org/articles/10.3389/fnut.2026.1730695/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky